Novartis (NVS) return on equity (ROE)
Novartis (NVS) earned a return on equity of 30.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.2 percentage points higher than the 27.1% of fiscal 2024. Figures as of 17 Nov 2026, 23:39 UTC, from Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- 30.3%
- Change on fiscal 2024
- +3.2 pts
- Highest on record
- 31.8%fiscal 2023
- Lowest on record
- 11.7%fiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Novartis return on equity (ROE), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was 31.8% in fiscal 2023 and the lowest 11.7% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 27.1%.
Return on equity by fiscal year
Novartis return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | 30.3% | 3.2 pts up | |
| 2024 | 27.1% | 4.7 pts down | |
| 2023 | 31.8% | 20.1 pts up | |
| 2022 | 11.7% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| AbbVie ABBV | 128.7% | 2024 |
| Merck & Co MRK | 34.7% | 2025 |
| UnitedHealth Group UNH | 12.8% | 2025 |
| Novartis NVS | 30.3% | 2025 |
| AstraZeneca AZN | 21.0% | 2025 |
| Thermo Fisher Scientific TMO | 12.6% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Novartis, figure by figure
- Novartis market cap
- Novartis revenue
- Novartis earnings
- Novartis earnings per share (EPS)
- Novartis P/E ratio
- Novartis P/S ratio
- Novartis P/B ratio
- Novartis free cash flow
- Novartis operating margin
- Novartis dividend
- Novartis shares outstanding
- Novartis total debt
- Novartis cash on hand
- Novartis total assets
- Novartis return on invested capital (ROIC)
Novartis (NVS) overview: price, valuation and scorecardAll health care companies by market value
Novartis return on equity (ROE): questions and answers
What is Novartis's return on equity?
Novartis (NVS) earned a return on equity of 30.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.2 percentage points higher than the 27.1% of fiscal 2024.
Is Novartis's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 27.1%.
What are the highest and lowest return on equity figures on record for Novartis?
Across the 4 fiscal years on record (2022–2025), the highest was 31.8% in fiscal 2023 and the lowest 11.7% in fiscal 2022.
How is Novartis's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Novartis (NVS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/NVS/roe
Underlying data: Yahoo Finance.